SLC16A3 and colorectal carcinoma: AZD3965, as a selective inhibitor of MCT-1 in CRC therapy, may cause an increase in circulating metabolic intermediates in the TCA cycle in MCT-4+ HT29 cells, which is further converted into bioenergy in HT29 cells(Table 1) (156, 157).